Literature DB >> 16302996

Primary alloproliferative TH1 response induced by immature plasmacytoid dendritic cells in collaboration with myeloid DCs.

M Naranjo-Gómez1, M A Fernández, M Bofill, R Singh, C V Navarrete, R Pujol-Borrell, F E Borràs.   

Abstract

The role played by dendritic cell (DC) subsets in the immune response to alloantigens is not well defined. In vitro experiments have extensively shown that freshly isolated myeloid (M)DCs induce a strong T lymphocyte proliferation whereas plasmacytoid (P)DCs do not, unless activated by CD40 ligation. The aim of these studies was to explore whether the interplay among PDCs, MDCs and T cells modulates alloresponse. Freshly isolated MDCs and PDCs were merged in different proportions and used as antigen presenting cells (APCs) in mixed lymphocyte cultures (MLC). As described, isolated PDCs only induced a mild alloresponse, while MDCs were potent inducers of alloproliferation. Unexpectedly, when PDCs were merged with even low numbers of MDCs (down to 100 cells) and used as APCs, a potent Th1 cell proliferation was detected. Survival and maturation of PDCs was increased in these MLC conditions, which could partially explain the magnitude of the T-cell response. Interestingly, the proportion of IFNgamma-producing cells generated in such cultures was higher compared to MDC-stimulated cultures. These data suggest that the interaction between both DC subsets is determinant to generate a potent Th1 response, at least in an allogeneic situation, and may be relevant to the outcome of allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302996     DOI: 10.1111/j.1600-6143.2005.01097.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  2 in total

1.  Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion.

Authors:  Mar Naranjo-Gómez; Nuria Climent; Joan Cos; Harold Oliva; Margarita Bofill; José M Gatell; Teresa Gallart; Ricardo Pujol-Borrell; Francesc E Borràs
Journal:  Immunology       Date:  2006-08-24       Impact factor: 7.397

2.  Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.

Authors:  Stefan Nierkens; Martijn H den Brok; Zacharias Garcia; Susan Togher; Jori Wagenaars; Melissa Wassink; Louis Boon; Theo J Ruers; Carl G Figdor; Stephen P Schoenberger; Gosse J Adema; Edith M Janssen
Journal:  Cancer Res       Date:  2011-07-25       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.